EPKINLY (Epcoritamab-bysp) Injection 4mg/48mg | AbbVie China | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: EPKINLY (Epcoritamab-bysp) Injection

EPKINLY (epcoritamab-bysp) is a CD20×CD3 bispecific antibody developed by Genmab and co-developed and co-commercialized with AbbVie. It is supplied as a ready-to-use solution for subcutaneous injection in two single-dose vial strengths: 4 mg/0.8 mL (used for the priming dose) and 48 mg/0.8 mL (the full therapeutic dose). This listing reflects the China-access version of EPKINLY, made available to patients in mainland China through authorized specialty drug channels.

What Is Epcoritamab (EPKINLY)?

Epcoritamab is a subcutaneous bispecific T-cell engager that is given on its own, without a lengthy hospital infusion. Unlike intravenous bispecific antibodies that often require step-up hospitalisation, EPKINLY was designed for convenient subcutaneous administration with a simple priming schedule. It belongs to the class of T-cell-engaging bispecific antibodies that bring a patient's own T cells directly into contact with malignant B cells. The "bysp" suffix distinguishes the approved biosimilar-named product, and the medicine is marketed under the brand name EPKINLY in the United States, Canada, Australia and Japan (and as Tepkinly in the EU and UK).

How Does Epcoritamab Work?

EPKINLY works through a dual-binding mechanism. One arm of the antibody binds to CD20, a protein expressed on the surface of mature B cells and most B-cell lymphomas. The other arm binds to CD3, a component of the T-cell receptor on cytotoxic T cells. By physically tethering a T cell to a CD20-positive lymphoma cell, epcoritamab triggers T-cell activation and directs the immune system to destroy the malignant B cell. This redirected T-cell killing is independent of the tumour's own immune-evasion signals, which is why it can produce responses in patients whose disease has progressed after multiple prior lines of therapy, including those who are not candidates for CAR T-cell therapy.

Indications of Epcoritamab

EPKINLY is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma. Its label also covers adults with relapsed or refractory follicular lymphoma (FL) after two or more prior systemic treatments. Because the treatment engages the immune system directly, patient selection, baseline testing and careful monitoring for cytokine-related reactions are essential parts of the prescribing workflow.

Dosage and Administration

EPKINLY is given by subcutaneous injection using a step-up dosing schedule to reduce the risk of cytokine release syndrome. Treatment typically begins with a small priming dose, followed by an intermediate dose, then the full 48 mg dose, administered in 28-day cycles. The 4 mg/0.8 mL vial is used for the lower priming steps, while the 48 mg/0.8 mL vial delivers the full dose. Pre-medication (corticosteroids, antihistamines and antipyretics) and adequate hydration are recommended before the first doses. EPKINLY should be administered by, or under the supervision of, a healthcare professional experienced in treating haematological malignancies.

Side Effects of Epcoritamab

The most important side effects of EPKINLY are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which carry a boxed warning. Common adverse reactions include fatigue, fever, injection-site reactions, musculoskeletal pain, diarrhoea, nausea, headache and low blood counts. Infections, including serious opportunistic infections, can occur. Patients are monitored closely during the early cycles, and the prescribing information includes detailed guidance on recognising and managing CRS and neurological toxicity. Treatment should be discussed thoroughly with the treating oncologist before starting.

Storage and Handling

EPKINLY vials must be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze and do not shake the vials. Once removed from refrigeration, the solution must be used within the time specified in the prescribing information. As a temperature-sensitive biologic, EPKINLY should be handled and transported under validated cold-chain conditions to preserve stability and efficacy.

Why Choose China-Sourced Epcoritamab?

For international patients and families seeking access to this important bispecific antibody, sourcing through China offers a practical pathway. Epcoritamab is a premium-priced therapy in Western markets, and the cost of a full treatment course can be a significant barrier. The China-access channel provides a more reachable route to the same branded product, supported by proper documentation and professional logistics. GLT works with licensed pharmaceutical partners to help patients obtain genuine, cold-chain-preserved EPKINLY with clear guidance on storage and administration. Every order is handled with the documentation and care required for a prescription biologic.

How to Order EPKINLY (Epcoritamab)

To enquire about EPKINLY availability, pricing and shipping, contact the GLT team directly. Share the prescribed dose (4 mg/0.8 mL or 48 mg/0.8 mL) and your location, and our team will confirm current stock, cold-chain delivery options and the documents required. Reach us on WhatsApp at +86 15234153837 or by email at [email protected]. A valid prescription is required, and this product is supplied only through authorised channels.

FAQ

Is EPKINLY approved in mainland China? EPKINLY received its first regulatory approval for relapsed/refractory DLBCL in 2023 and has since been authorised in more than 30 countries. In mainland China, the medicine is currently accessible through the Hainan Boao Lecheng special drug import channel, which allows patients to obtain approved international medicines ahead of nationwide regulatory approval.

What strengths are available? EPKINLY is supplied in 4 mg/0.8 mL and 48 mg/0.8 mL single-dose vials. The 4 mg vial is used for the initial priming doses and the 48 mg vial for the full therapeutic dose.

How should EPKINLY be stored? Keep vials refrigerated at 2°C to 8°C, protected from light. Do not freeze or shake. GLT ships under validated cold-chain conditions to maintain product integrity.

Is EPKINLY covered by China's national medical insurance? As the medicine is not yet formally approved and launched nationwide, it is not included in the national reimbursement list at present. Patients obtain it through the special import channel or private funding.

Who can use EPKINLY? EPKINLY is intended for adults with relapsed or refractory DLBCL or FL after two or more prior lines of systemic therapy, under the supervision of a haematologist or oncologist.

Related Oncology Products

Ponatinib (Iclusig) 45mg Tablets | BCR-ABL T315I Inhibitor | GLT

Third-generation BCR-ABL TKI for T315I-positive CML and Ph+ ALL

Mozobil (Plerixafor) 24mg/1.2mL Injection China | Sanofi | GLT

Plerixafor (Mozobil) 24mg/1.2mL single-dose vial, CXCR4 antagonist for haematopoietic stem-cell mobilization in NHL and multiple...

Ponatinib (LuciPona) 15mg/45mg Tablets | Laos Generic | GLT

Generic BCR-ABL TKI for T315I-positive CML and Ph+ ALL

PHOIXAZ (Ixazomib) 4mg | Generic Proteasome Inhibitor | Pharma 2 Vientiane | GLT

Generic ixazomib (oral proteasome inhibitor) by Pharma 2 Vientiane (Laos) — an affordable alternative to...

Isadx (Ixazomib) 4mg | Generic Proteasome Inhibitor | BigBear Pharmaceutical Co., Ltd. | GLT

Generic ixazomib (oral proteasome inhibitor) by BigBear Pharmaceutical Co., Ltd. (Laos) — an affordable alternative...

Ponatinib (Ponaxen) 15mg/45mg Tablets | Bangladesh Generic | GLT

Generic BCR-ABL TKI for T315I-positive CML and Ph+ ALL